Grand Fortune Capital (HK) Company Limited reported a 19.1% beneficial stake in Baird Medical Investment Holdings Ltd. The Schedule 13D was filed on Jul. 31, 2026, following the company’s business combination with ExcelFin Acquisition Corp. The position suggests Grand Fortune Capital (HK) could engage with management on strategy and future deals.

Investor Intent

Grand Fortune Capital (HK) holds the shares for investment but plans to stay involved. It "may engage in discussions with the Issuer's management and board of directors regarding the Issuer's business, operations, capitalization, corporate governance, [and] strategic transactions," including financings, asset sales, mergers, or other combinations.

The group keeps flexibility to change its position. It "may from time to time acquire additional securities of the Issuer or dispose of some or all of the securities" as circumstances evolve.

Investor's Background

Grand Fortune Capital (HK) Company Limited is a Hong Kong investment holding company that controls Grand Fortune Capital LLC and oversees ExcelFin SPAC LLC. ExcelFin served as the sponsor of ExcelFin Acquisition Corp., which combined with Baird Medical Investment Holdings Ltd. The group focuses on event-driven opportunities such as SPAC sponsorships and structured investments around corporate transactions.

Original SEC Filing: Baird Medical Investment Holdings Ltd [ BDMD ] - SCHEDULE 13D - Jul. 31, 2026